Novel population pharmacokinetic approach to explain the differences between cystic fibrosis patients and healthy volunteers via protein binding

URN to cite this document:: urn:nbn:de:bvb:355-epub-416095
DOI to cite this document:: 10.5283/epub.41609

Shah, Nirav R. ; Bulitta, J. B.

; Kinzig, M. ; Kees, Frieder ; ;

; ; ; ; ; ;

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(2MB)

Date of publication of this fulltext: 14 Feb 2020 13:41

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

The pharmacokinetics in patients with cystic fibrosis (CF) has long been thought to differ considerably from that in healthy volunteers. For highly protein bound beta -lactams, profound pharmacokinetic differences were observed between comparatively morbid patients with CF and healthy volunteers. These differences could be explained by body weight and body composition for beta -lactams with low ...